- Conditions: Elderly; Pharmaceutical Care; Hospital Readmission; Health Services for the Aged; Medication Safety
Intervention: Other: Pharmaceutical Care Service
Sponsors: RWTH Aachen University; RWTH Aachen University; Apothekerstiftung Nordrhein, Duesseldorf; Foerderinitiative Pharmazeutische Betreuung e.V., Berlin
Recruiting - verified May 2012 - Condition: Acute Vertigo
Interventions: Drug: V0251; Drug: placebo
Sponsors: Pierre Fabre Medicament; Pierre Fabre Medicament
Not yet recruiting - verified April 2012 - Condition: Cushing's Disease
Intervention: Drug: Pasireotide sub-cutaneous formulation
Sponsors: Novartis; Novartis Pharmaceuticals
Available - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: fostamatinib; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Sponsors: Johannes Gutenberg University Mainz; Johannes Gutenberg University Mainz; Roche Pharma AG
Not yet recruiting - verified April 2012 - Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Drug: dalcetrapib; Drug: Placebo; Other: Background care
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Hypercholesterolemia; Coronary Heart Disease
Interventions: Drug: mipomersen sodium 200 mg; Drug: Placebo; Drug: mipomersen sodium 70 mg
Sponsors: Genzyme; Genzyme
Recruiting - verified December 2011 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503; Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: BMS-833923
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011 - Conditions: Head and Neck Neoplasms; Carcinoma, Squamous Cell
Interventions: Drug: Afatinib; Drug: Methotrexate; Drug: Methotrexate
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Prostate Cancer Metastatic
Interventions: Drug: EMD 525797; Drug: EMD 525797; Other: Placebo
Sponsors: EMD Serono; EMD Serono
Recruiting - verified May 2012 - Conditions: Diabetes Mellitus; Macular Edema
Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Biological: VEGF Trap-Eye (BAY86-5321); Procedure: Laser treatment
Sponsors: Bayer; Bayer; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: PegIFN/RBV; Drug: BI 201335
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: rituximab [MabThera/Rituxan]; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Malignant Melanoma
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Severe COPD
Intervention: Drug: Daxas
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012 - Condition: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Interventions: Drug: S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm); Drug: Fluorouracil/cisplatin (control arm)
Sponsors: Taiho Pharma USA, Inc.; Taiho Pharma USA, Inc.
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Radiation: radiation therapy
Sponsors: Swiss Group for Clinical Cancer Research; Swiss Group for Clinical Cancer Research
Recruiting - verified May 2012 - Conditions: Shock, Hemorrhagic; Shock, Traumatic; Acidosis, Lactic
Interventions: Drug: MP4OX; Drug: Saline
Sponsors: Sangart; Sangart
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Delirium
Interventions: Drug: Xenon; Drug: Sevoflurane
Sponsors: Air Liquide Santé International; Air Liquide Santé International; i3 Innovus
Recruiting - verified April 2012 - Condition: Kidney Disease, Chronic
Interventions: Drug: Mircera; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: temsirolimus; Drug: temsirolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Schizophrenia
Interventions: Drug: Olanzapine; Drug: Flupentixol; Drug: Quetiapine; Drug: Aripiprazole; Drug: Haloperidol
Sponsors: University of Bremen; University of Bremen; German Federal Ministry of Education and Research
Recruiting - verified April 2012 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Acute Ischemic Stroke
Intervention: Device: NeuroThera® Laser System
Sponsors: PhotoThera, Inc; PhotoThera, Inc
Recruiting - verified April 2012 - Condition: Acute Cellular Rejection
Interventions: Drug: Rituximab; Drug: Placebo
Sponsors: Hannover Medical School; Hannover Medical School; German Research Foundation
Recruiting - verified May 2012 - Condition: Renal Transplantation
Interventions: Drug: Everolimus; Drug: Prograf or Neoral
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Fracture Healing
Interventions: Drug: Placebo; Drug: AMG 785 140 mg; Drug: AMG785 70mg; Drug: AMG 785 210mg
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Leukemia, Myeloid
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: OFATUMUMAB + DHAP; Drug: RITUXIMAB + DHAP
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Glioblastoma Multiforme
Interventions: Drug: bevacizumab [Avastin]; Drug: irinotecan; Drug: temozolomide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Fracture Healing
Interventions: Drug: AMG 785 210mg; Drug: AMG 785 70mg; Drug: AMG 785 140 mg; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Hypertension, Pulmonary
Intervention: Drug: ambrisentan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: Aspergillosis; Invasive Fungal Infections
Intervention: Drug: isavuconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012 - Conditions: Invasive Fungal Infection; Aspergillosis
Interventions: Drug: Isavuconazole; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
 |
Join Clinical Trials that are Held in Aachen, Germany |
Clinical Trial Locations 